anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
As many as 80 percent of AIDS patients experience at least one episode of PCP and about one-third of these patients have a recurrence of the disease. Drugs currently used for treatment of acute PCP are toxic to the majority of AIDS patients. The combination of clindamycin and primaquine reduces the numbers of PCP organisms in laboratory tests and in animal studies. Both drugs can be given orally, concentrate in lung tissue, and have been used safely in humans for treatment of other diseases. It is possible that the combination may prove to be as good or better than standard therapy for PCP and side effects may be less.

The proposal for the first 20 patients enrolled in ACTG 044 initially called for an open-labelled, pilot study of intravenous (IV) clindamycin and primaquine therapy in patients with mild to moderate PCP. Preliminary results of the first 22 patients entered into ACTG 044 indicate that the response rate to therapy was over 90 percent. The rate of discontinuation secondary to toxic side effects was only 20 percent. Additional uncontrolled studies have shown an excellent clinical response and safety profile in another 60 patients. The protocol has been amended to provide an all oral dosing regimen. An additional 20 patients with mild PCP will be enrolled and tested with oral clindamycin and primaquine on an outpatient basis. All patients will receive clindamycin and primaquine. Total duration of therapy will be 21 days. Patients may be hospitalized at any time during the study as clinically indicated. Treatment with zidovudine may be started or resumed after completion of clindamycin / primaquine therapy.

AMENDED: An additional 30 patients instead of 20 patients with mild PCP will be enrolled.
PURPOSE: The prognostic factors of subsequent liver transplantation (LT) in patients with biliary atresia (BA) who presented with jaundice-free native liver survival were investigated.
METHODS: This study retrospectively reviewed patients who underwent portoenterostomy (PE) for BA. Patients with jaundice-free native liver survival at 1 year postoperatively were divided into the autologous liver survivor and liver transplant recipient groups. Peri- and postoperative data were compared between the two groups.
RESULTS: Among 97 patients with BA, 29 who received LT within 1 year after PE were excluded from the analysis. Further, 48 patients currently living with native liver and 20 who received LT after 1 year postoperatively were compared. Bile lake (BL) was the strongest risk factor of LT. The risk score was 2.38  ∗ B L s c o r e + 0.00466  ∗ T B A  , and the area under the receiver operating characteristic curve was 0.83. Patients with BL and those without significantly differed in terms of the native liver survival rate. Patients with BL who presented with not only cholangitis but also gastrointestinal hemorrhage and hepatopulmonary syndrome received LT.
CONCLUSION: BL can cause different pathologies. Moreover, it is an evident risk factor of subsequent LT in patients with BA who are living with native liver at 1 year after PE.
PURPOSE: A composition containing Jasminum grandiflorum extract for whitening is provided to suppress melanogenesis and enhance whitening effect without cytotoxicity. CONSTITUTION: A composition for whitening contains Jasminum grandiflorum extract. The Jasminum grandiflorum extract is obtained through polar solvent selected from water, low alcohol of 1-4 carbon atoms or mixture solvent. A cosmetic composition contains the 0.001-50 weight% of Jasminum grandiflorum extract and dermatologically acceptable carrier. The cosmetic composition is used in the form of nutrition lotion, cream, essence, and skin softener. A food composition contains the Jasminum grandiflorum extract and sitologically acceptable carrier.
A medicinal prepn. mainly for treatment of arthritic and rheumatic complaints contains aliginate, a mined mineral, a suitable carrier or a suspending agent. Alginate is crushed , dried in air at 60 deg.C. max. until a moisture content of less than 15% is reached. Finally the mineral is mulled to less than 50 micron size in a high velocity air-stream mill, causing particles to collide. Glycerol is added to the powder to prepare a cream.
This pilot trial will treat subjects in the ECP Group with ECP derived from two donors. ECP will be provided as ECPSDU each comprising 90 - 110mL of plasma from two individual ABO-compatible donors. Two ECPSDU will be administered as immediately sequential infusions. Subjects may receive up to three doses of ECP not less than 48 hours apart. ECP will be provided as Plasma Frozen Within 24 Hours After Phlebotomy (PF24) as described in Section 6.1. Pre-treatment and frequent post-treatment blood specimens for assay of anti-EBOV antibody and EBOV viral load by RT-PCR will be obtained from subjects. The pharmacodynamic effect of ECP anti-EBOV, including neutralization titers, on viral load will be examined in the ECP Group. Changes of individual and treatment group clinical and laboratory parameters with time will be described. Between-group and within-group will examine interactions of clinical parameters, outcome, ECP total dose, EBOV viral load, and anti-EBOV (IgG ELISAs for Zaire GP residues 1-649 and irradiated Zaire virus, and anti-EBOV PRNT). The MEWS will be assessed as a prognostic tool in the Screened Control Group. Efficacy of ECP will be assessed primarily by comparison of survival to hospital discharge between the ECP Group and the Screened Control Group.
PROBLEM TO BE SOLVED: To provide a prescription issuing system which can efficiently be operated. SOLUTION: A patient access a hospital receptionist terminal 2 and presents an ID number. The hospital receptionist terminal 2 extracts the medical sheet information of the patient based on a presented ID number and transmits the prescription request and medical sheet information of a user to a medical doctor terminal 3, which makes judgment about prescription based on the medical sheet information, and issues prescription information. The hospital receptionist terminal 2 requests a prescription issuing fee to a user terminal 1, which instantly settles this by payment with a card or electronic money. When settlement is completed, the hospital receptionist terminal 2 sends an exchange certificate to the user terminal 1 and a pharmacy terminal 4. The user visits the pharmacy, presents the exchange certificate to the pharmacy, and the pharmacy transfers drug to the patient.
Safety and effectiveness in pediatric patients with HIV have not been established. Available evidence suggests that somatropin clearance is similar in adults and children, but no pharmacokinetic studies have been conducted in children with HIV.

In two small studies, 11 children with HIV-associated failure to thrive were treated subcutaneously with human growth hormone. In one study, five children (age range, 6 to 17 years) were treated with 0.04 mg/kg/day for 26 weeks. In a second study, six children (age range, 8 to 14 years) were treated with 0.07 mg/kg/day for 4 weeks. Treatment appeared to be well tolerated in both studies. The preliminary data collected on a limited number of patients with HIV-associated failure to thrive appear to be consistent with safety observations in growth hormone-treated adults with HIV wasting.

Benzyl alcohol, a component of this product, has been associated with serious adverse events and death, particularly in pediatric patients. The "gasping syndrome," (characterized by central nervous system depression, metabolic acidosis, gasping respirations, and high levels of benzyl alcohol and its metabolites found in the blood and urine) has been associated with benzyl alcohol dosages >99 mg/kg/day in neonates and low-birth weight neonates. Additional symptoms may include gradual neurological deterioration, seizures, intracranial hemorrhage, hematologic abnormalities, skin breakdown, hepatic and renal failure, hypotension, bradycardia, and cardiovascular collapse. Practitioners administering this and other medications containing benzyl alcohol should consider the combined daily metabolic load of benzyl alcohol from all sources.
Tension pneumocephalus (TP) after spinal surgery is very rare with only a few cases reported in the English literature. Most cases of TP occur rapidly after spinal surgery. Traditionally, TP is managed using burr holes to relieve intracranial pressure. However, our case highlights a rare delayed presentation of TP and pneumorrhacis 1 month after routine cervical spine surgery. It is to our knowledge the first case of TP after spinal surgery to be treated using dural repair and supportive care. A 75-year-old woman presented with TP after having routine cervical decompression and stabilisation for cervical myelopathy. She re-presented 1 month after her initial operation with a leaking wound and altered mental status, which deteriorated rapidly shortly after admission. This, in combination with her radiographic features, influenced the decision to explore her surgical wound emergently. She made a full recovery and was discharged after 2 weeks in hospital. We hope to emphasise the need for a high index of suspicion for cerebrospinal fluid leaks and the low threshold to return to theatre to repair a potential dural defect, as well as illustrate that TP after spinal surgery can be treated successfully without burr holes.
Symptoms following acute NSAID overdosages have been typically limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain, which have been generally reversible with supportive care. Gastrointestinal bleeding has occurred. Hypertension, acute renal failure, respiratory depression, and coma have occurred, but were rare [see Warnings and Precautions (5.1, 5.2, 5.4, 5.6)].

Manage patients with symptomatic and supportive care following an NSAID overdosage. There are no specific antidotes. Consider emesis and/or activated charcoal (60 to 100 grams in adults, 1 to 2 grams per kg of body weight in pediatric patients) and/or osmotic cathartic in symptomatic patients seen within four hours of ingestion or in patients with a large overdosage (5 to 10 times the recommended dosage). Forced diuresis, alkalinization of urine, hemodialysis, or hemoperfusion may not be useful due to high protein binding 

There is limited experience with meloxicam overdosage. Cholestyramine is known to accelerate the clearance of meloxicam. Accelerated removal of meloxicam by 4 g oral doses of cholestyramine given three times a day was demonstrated in a clinical trial. Administration of cholestyramine may be useful following an overdosage. 

For additional information about overdosage treatment, call a poison control center (1-800-222-1222).
Participants randomized to the WLC condition will receive one session of ART adherence counseling immediately following randomization. After six months, WLC participants will have the opportunity to receive 12 individually delivered CBT-AD sessions focused on depression.
In base study P05714 (NCT00696878), up to 3 COS cycles were performed, each including the following: A single injection of 150 µg corifollitropin alfa was administered on Day 2 or 3 of the menstrual cycle (Stimulation Day 1). Administration of Gonadotropin Releasing Hormone (GnRH) antagonist (0.25 mg/day) started on Stimulation Day 5 or 6 and continued through day of administration of recombinant Human Chorion Gonadotropin (\[rec\]hCG) (5,000-10,000 IU/250 µg). Daily dosing with Follicle Stimulating Hormone (FSH) (not to exceed 225 IU/day) began on Stimulation Day 8 and continued up to day of (rec)hCG administration. Progesterone was administered for luteal phase support. After COS cycles 1 and 2, Frozen-Thawed Embryo Transfer cycles (up to 3 after each COS cycle) could occur. Participants with confirmed pregnancy at least 10 weeks after fresh embryo transfer in the base study were eligible for this follow-up study. In this follow-up study P05715, no study drugs were administered.
Lucitanib given orally once daily on a continuous schedule. Starting dose is 10 mg/day.
1479098 Benzodiazocine derivatives DDSA PHARMACEUTICALS Ltd 21 May 1976 [19 June 1975] 26065/75 Heading C2C The invention comprises compounds of general Formula I and acid addition salts of these compounds; R 1  represents halogen, trifluoromethyl, cyano, nitro, lower alkyl, lower alkoxy or lower alkylthio; R 2  represents a lower alkyl or benzyl group; -A- represents a group or a group  R 3  represents phenyl, (lower alkyl)-phenyl, nitrophenyl, halophenyl or pyridyl; R 4  represents an aromatic group, the aromatic ring of which is directly attached to the benzodiazocine ring, e.g. a furyl, phenyl or substituted phenyl group; "lower" here signifies C 1 -C 6 . A compound of Formula I may be made by reacting a benzodiazepine compound of formula in solution in aqueous acid with an aldehyde R 4 CHO, and converting the resulting intermediate into a compound of Formula I by dissolving it in a solvent (e.g. isopropanol) under basic conditions. Compounds of Formula I exemplified are 8-chloro-2-methylamino-4,6- diphenyl - 1,5 - benzodiazacine - 5 - oxide and the corresponding compound in which the phenyl group in the 4-position is replaced by a furyl group. The compounds may be used in therapuetic compositions.
For the Functional Star-shape taping (FST) procedure, four tapes will be applied in the form of an elastic ''I'' with the aim of facilitating muscle activation. The taping will be applied when the participant is in a seated position. The taping will be positioned covering the entire lumbar region and lower part of the thoracic region (T11, T12), and placed first at the center and then on the ends (Castro-Sanchez et al. 2012).The tension of the taping was 25%, this protocol being recommended by the Kinesio taping manual to facilitate muscle activation (Castro-Sanchez et al. 2012; Kase et al. 2003). The participant will remain for on week with FT.
Catheter-associated urinary tract infections (CAUTIs) are amongst the most common nosocomial infections worldwide and are difficult to treat partly due to development of multidrug-resistance from CAUTI-related pathogens. Importantly, CAUTI often leads to secondary bloodstream infections and death. A major challenge is to predict when patients will develop CAUTIs and which populations are at-risk for bloodstream infections. Catheter-induced inflammation promotes fibrinogen (Fg) and fibrin accumulation in the bladder which are exploited as a biofilm formation platform by CAUTI pathogens. Using our established mouse model of CAUTI, here we identified that host populations exhibiting either genetic or acquired fibrinolytic-deficiencies, inducing fibrin deposition in the catheterized bladder, are predisposed to severe CAUTI and septicemia by diverse uropathogens in mono- and poly-microbial infections. Furthermore, here we found that Enterococcus faecalis, a prevalent CAUTI pathogen, uses the secreted protease, SprE, to induce fibrin accumulation and create a niche ideal for growth, biofilm formation, and persistence during CAUTI.
This open-label, phase II, dose-escalation study will be conducted in human subjects seeking repair of modest (approx. 5-30cc) soft tissue defects of the trunk (n=15). All participants will be treated via permanent injection of the study intervention (AAT injection) to restore the defect's contour. All study data will be collected in Case Report Forms (CRFs) and entered into a customized study database, created and maintained in HIPAA-compliant Research Electronic Data Capture (REDCap) software (14).
BACKGROUND: Orthostatic intolerance occurs following immobilization in patients on Earth and in astronauts after spaceflight. Head-down tilt bedrest is a terrestrial model for weightlessness and induces orthostatic intolerance. We hypothesized that lower-body negative pressure (LBNP) or cycling followed by wearing venous constrictive thigh cuffs mitigates orthostatic intolerance after head-down tilt bedrest.
METHODS AND RESULTS: We enrolled 47 healthy individuals (20 women, 35±9 years) to a 30-day strict head-down tilt bedrest study. During bedrest, they were assigned to 6 hours of 25 mm Hg LBNP (n=12) per day and 1 hour of supine cycling followed by 6 hours of venous constriction through thigh cuffs 6 days per week (n=12), 6 hours of daily upright sitting (positive control, n=11), or no countermeasure (negative control, n=12). We measured orthostatic tolerance as the time to presyncope during 80° head-up tilt testing with incremental LBNP before and immediately after bedrest. We determined plasma volume with carbon monoxide rebreathing before and at the end of bedrest. After bedrest, orthostatic tolerance decreased 540±457 seconds in the control group, 539±68 seconds in the cycling group, 217±379 seconds in the LBNP group, and 289±89 seconds in the seated group (P<0.0001 time point, P=0.009 for group differences). Supine and upright heart rate increased in all groups following bedrest. Plasma volume was only maintained in the cycling group but decreased in all others (interaction countermeasure×time point P<0.0001).
CONCLUSIONS: Six hours of moderate LBNP training was as effective as sitting in attenuating orthostatic intolerance after 30 days of head-down tilt bedrest. Daily cycling exercise followed by 6 hours of wearing venous constrictive thigh cuffs, while maintaining plasma volume, did not improve orthostatic tolerance.
REGISTRATION: URL: https://www.bfarm.de/EN; Identifiers: DRKS00027643 and DRKS00030848.
This utility model provides a dynamic inhalation contamination experimental installation about materials in solid dust type, which includes an instrument mainly controlled by a computer, the contaminated room for animals with isolated doors. At the bottom of the end of the animal contamination room combines the adjustable rotatable dust emission producer, which is linked with the jet equipment whose flux is adjustable by controlling pressure. The electric motor operated by the computer-directed main controller is connected with the dust emission producer through rotational flexible shaft. At the bottom of the animal contamination room equips with an amplification port of the sample which is of the release-proof dust sample type, while inside of the middle part with animal fixing frame. Both sides of the middle part of the animal contamination room, being adjacent to the animal fixing frame are equipped with the dust sampler and temperature and humidity sampler. On the top and inside of the animal contamination room, there is the homogeneous fan, blowing laterally. The air filter in the same room is connecting with the vibration separating dust sieve. On the utmost top of the animal contamination room links the waste gas absorbing apparatus through the waste gas pipe. This product enables any materials in solid dust type to take the dynamic inhalation contamination experiment, solving the technical problem in this field.
A therapy planning system and method generate an optimal treatment plan accounting for changes in anatomy. Therapy is delivered to the subject according to a first auto-planned optimal treatment plan based on a first image of a subject. A second image of the subject is received after a period of time. The second image is registered with the first image to generate a deformation map accounting for physiological changes. The second image is segmented into regions of interest using the deformation map. A mapped delivered dose is computed for each region of interest using the dose delivery goals and the deformation map. The first treatment plan is merged with the segmented regions of the second image and the mapped delivered dose during optimization.
The invention relates to a magnesium stearate applicable to pharmaceutical preparations and a preparation method thereof. The magnesium stearate is composed of the following components in parts by weight: 8-10 parts of stearic acid, 1.2-1.8 parts of magnesium hydroxide and 0.1-0.5 part of catalyst. The magnesium stearate is prepared by a one-step preparation process in a kneader. The C18 content in the stearic acid is 43% above, and the magnesium content in the magnesium hydroxide is up to 98% above. The catalyst adopts oxydol or ammonia water. The preparation method comprises the following steps: adopting a purchasable kneader, proportionally adding all the components into the kneader, and kneading for 1.6-2.4 hours while controlling the temperature at 100-120 DEG C. The magnesium stearate has the characteristics of wide raw material sources, simple preparation technique and the like, and can be especially used in pharmaceutical preparations.
293,090. Carpmael, W., (I. G. Farbenindustrie Akt.-Ges.). March 25, 1927. Medicaments for external application; special shapes and forms; suppositories; bougies and pessaries composed of medicaments. - Medicaments in the form of elastic, mechanically resistant, and readily soluble sticks, balls, or other shaped forms are prepared with a basis or carrier consisting of gum tragacanth, or other gum or mucilage of similar elastic properties, rendered readily soluble in water by the addition of a hydrotropic substance such as the sodium salt of p-toluene sulphonic acid or the sodium salt of sulphanilic acid. Succus liquiritia and other indifferent water-soluble substances such as borax or milk sugar may also be added. According to an example protargol is the active medicament employed. The prior use of sticks having a basis of cocoa-butter or containing glycerine-gelatine or also dextrine, sugar, starch, or glycerine is referred to. Specification 218.323 is referred to.
Postoperative atrioventricular block may occur after pediatric cardiac surgery. A small proportion of those who develop atrioventricular block will require pacemaker placement. The primary aim of this study was to determine factors associated with postoperative atrioventricular block. Secondary aims included determining factors associated with pacemaker placement in those with atrioventricular block. Data from the PHIS data were utilized to identify patients under 18 years of age who underwent cardiac surgery. Those who did and did not develop atrioventricular block. Univariable analyses and regression analyses were conducted to determine factors associated with postoperative atrioventricular block. Similar analyses were conducted to determine factors associated with pacemaker placement in those with atrioventricular block. A total of 43,716 admissions were identified. Of these, 2093 (5%) developed atrioventricular block and 480 (1% of total admissions) underwent pacemaker placement. Approximately 70% of those with atrioventricular block received steroids but this was not associated with a decrease in pacemaker placement. Risk factors (congenital malformations of the heart, comorbidities, medications) associated with increased risk of atrioventricular block and pacemaker placement were identified. Postoperative atrioventricular block occurred in 5% of pediatric admissions for cardiac surgery. Of these admissions with postoperative atrioventricular block, 23% required pacemaker placement. Isoproterenol and steroids were not associated with a reduction in the likelihood of pacemaker placement.
US-guided injection will be performed with a 5-12 MHz linear transducer (Logic e portable; GE Healthcare, China) by the same physiatrist and injections will be administered into the subacromial bursa with a posterolateral approach. A mixture of 1 mL corticosteroid (betamethasone 3 mg/mL) and 1 mL lidocaine (20 mg) will be injected (1 session).